应用治疗公司(APLT.O)今日盘前大跌71.76%,引发了市场的广泛关注。
消息面上,导致该公司股价暴跌的主要原因是美国食品和药物管理局(FDA)昨日拒绝批准该公司治疗半乳糖血症药物govorestat。FDA表示govorestat的临床申请存在不足之处,这让这款新药产品的未来陷入重大困境。
分析人士指出,govorestat作为该公司一款潜力巨大的新药在道路上遭受重创,意味着公司的主要收入增长来源受到了冲击。因此,市场对公司未来前景产生了巨大担忧,从而引发了股价剧烈反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.